

QUARTERLY DEALS & MARKET UPDATE

Healthcare Tech

November 2019







Medical Bill Servicing



Overview of Evolve Capital Partners

ABOUT EVOLVE CAPITAL PARTNERS

- Evolve Capital Partners (Evolve) is a specialized investment bank focused on businesses serving industries at the intersection of finance and technology.
- We are dedicated investment bankers focused on evolving industries, and we support sustainable growth through transformational M&A / financing transactions.
- Evolve is a dedicated, creative, and fully independent investment bank that advises private and public companies on merger, divestiture and acquisition transactions, and capital raising through private placements.
- We also provide structured financial advisory services our investment banking practice provides a comprehensive suite of solutions to businesses.
- With over 30 engagements executed by its leaders, Evolve has served as a proud partner, bringing renewed value to companies at the intersection of finance and technology.
- Founded in 2012 and based in New York, NY.

HIGH-TOUCH INVESTMENT BANKING

Few investment banks have transaction experience across both corporate and asset finance.



Our Clients

- Corporations
- Management Teams
- VC & PE Backed Companies
- IndependentDirectors / Boards



Investment Banking Advisory

- M&A
- StrategicAlliances
- Capital Raises and Asset Finance
- Financial Restructuring



Industry Focus

Finance and Technology Firms

Securities Specialty Finance Payments BPO
Financial Services Enterprise Software Lending IoT
Financial Management Analytics Insurance B2B

Evolve Capital Partners; Deals & Market Update - Healthcare Tech 2



We Focus Exclusively on Finance and Technology-Related Firms

























Market Summary and Key Multiples

Industry Stock Market Performance of Evolve Sector Coverage

Indexed Price Performance *

Sector	3 Months	1 Year	3 Years
Bank Tech / Solutions	(2.3%)	18.4%	60.1%
ВРО	(1.3%)	11.8%	63.8%
Enterprise Software / Data & Analytics	(0.8%)	13.9%	51.3%
Financial Management Solutions	0.7%	32.0%	107.4%
Healthcare Tech	(1.2%)	(2.1%)	62.2%
Insurance	0.6%	12.7%	60.3%
Payments	(4.9%)	12.5%	105.3%
Securities	2.2%	4.7%	35.4%
Specialty Finance / Alternative Lending	1.9%	7.8%	52.2%


^{*} Equal weighting method.

Industry-wide Multiples and Subsector Multiples

Sector 2020E Price / Earnings Multiples

Financial Management 47.7x Solutions Healthcare Tech 35.6x Enterprise Software / Data 34.8x & Analytics **Payments** 31.5x BPO 31.0x Bank Tech / Solutions 30.0x Securities 20.8x Insurance 18.4x Specialty Finance / 10.7x Alternative Lending

Healthcare Tech 2020E Price / Earnings Multiples



Data as of November 1, 2019 Source: Pitchbook



Stock Comparables – Healthcare Tech Sub-Sectors

(All figures in millions of USD, except per share data. Data as of November 1, 2019)

							Growth	Rates:						
	Stock	% of 52-	Market	Enterprise	LT	M	Revenue:	Earnings	LTM M	argins:	EV / R	evenue	EV / E	BITDA
	Price	Wk. High	Value	Value	Revenue	EBITDA	CY 2019	LT	Gross	EBITDA	LTM	CY 2019	LTM	CY 2019
Cerner	\$67.53	88.3%	\$21,211	\$21,617	\$5,616	\$1,313	11%	(6%)	82%	23%	3.8x	3.8x	16.5x	13.1x
CompuGroup Medical	\$64.71	77.2%	\$3,160	\$3,524	\$824	\$191	23%	34%	83%	23%	4.3x	4.4x	18.4x	17.4x
Allscripts Healthcare Solutions	\$11.19	90.2%	\$1,865	\$2,688	\$1,587	\$43	20%	NA	41%	3%	1.7x	1.5x	63.1x	8.9x
NextGen Healthcare	\$16.99	80.4%	\$1,112	\$1,120	\$532	\$66	2%	NA	52%	12%	2.1x	2.1x	17.0x	14.3x
HealthStream	\$27.96	93.2%	\$905	\$764	\$251	\$44	18%	30%	58%	18%	3.0x	3.0x	17.2x	16.9x
EMIS Group	\$13.64	85.8%	\$863	\$833	\$227	\$68	(2%)	81%	92%	30%	3.7x	4.1x	12.2x	14.6x
Evolent Health	\$7.80	28.9%	\$659	\$880	\$733	(\$47)	93%	NA	44%	(6%)	1.2x	1.0x	NMF	NMF
Computer Programs & Systems	\$23.06	67.8%	\$331	\$461	\$277	\$37	(2%)	27%	53%	14%	1.7x	1.7x	12.3x	9.6x
NantHealth	\$0.71	36.3%	\$79	\$289	\$95	(\$142)	13%	NA	54%	(150%)	3.1x	2.9x	NMF	NMF
MEAN							19%	33%	62%	(4%)	2.7x	2.7x	22.4x	13.5x
MEDIAN							13%	30%	54%	14%	3.0x	2.9x	17.0x	14.3x

Health Insurance Solutions

							Growth	Rates:						
	Stock	% of 52-	Market	Enterprise	L1	ГМ	Revenue	Earnings	LTM M	argins:	EV / R	evenue	EV / E	BITDA
	Price	Wk. High	Value	Value	Revenue	EBITDA	CY 2019	LT	Gross	EBITDA	LTM	CY 2019	LTM	CY 2019
UnitedHealth Group	\$252.21	87.6%	\$239,015	\$270,082	\$234,166	\$21,204	21%	28%	23%	9%	1.2x	1.1x	12.7x	12.2x
Anthem	\$270.75	85.1%	\$68,652	\$84,692	\$100,179	\$7,350	15%	24%	NA	7%	0.8x	0.8x	11.5x	11.2x
Humana	\$296.20	83.2%	\$40,013	\$41,165	\$60,726	\$4,087	20%	41%	NA	7%	0.7x	0.6x	10.1x	11.1x
Centene	\$52.13	70.0%	\$21,571	\$21,718	\$72,335	\$2,892	53%	32%	12%	4%	0.3x	0.3x	7.5x	7.5x
WellCare Health Plans	\$293.33	97.4%	\$14,763	\$13,143	\$26,983	\$1,212	65%	38%	12%	4%	0.5x	0.5x	10.8x	10.4x
Molina Healthcare	\$118.83	74.7%	\$7,451	\$4,502	\$17,084	\$1,188	(15%)	73%	14%	7%	0.3x	0.3x	3.8x	4.0x
Maximus	\$75.80	92.4%	\$4,837	\$4,770	\$2,690	\$378	22%	13%	24%	14%	1.8x	1.6x	12.6x	11.1x
Nuance	\$15.96	96.8%	\$4,559	\$5,809	\$2,041	\$307	(5%)	NA	59%	15%	2.8x	3.2x	18.9x	NA
Magellan Health	\$67.05	88.4%	\$1,641	\$1,627	\$7,201	\$175	23%	(51%)	2%	2%	0.2x	0.2x	9.3x	5.6x
Triple-S Management	\$15.43	55.8%	\$360	\$394	\$3,172	\$86	13%	16%	NA	3%	0.1x	0.1x	4.6x	NA
Health Insurance Innovations	\$25.33	48.9%	\$359	\$526	\$357	\$34	80%	15%	NA	9%	1.5x	1.2x	15.6x	6.3x
MEAN	***************************************	*******************************	***************************************		***************************************		27%	23%	21%	7%	0.9x	0.9x	10.7x	8.8x
MEDIAN							21%	26%	14%	7%	0.7x	0.6x	10.8x	10.4x

Healthcare IT / Analytics

				•	•		Growth	Rates:	•	, and the second	, and the second		, and the second	, and the second
	Stock	% of 52-	Market	Enterprise	LT	M	Revenue	Earnings	LTM M	argins:	EV / R	evenue	EV /	EBITDA
	Price	Wk. High	Value	Value	Revenue	EBITDA	CY 2019	LT	Gross	EBITDA	LTM	CY 2019	LTM	CY 2019
Omnicell	\$71.03	76.7%	\$2,979	\$2,982	\$860	\$136	25%	80%	48%	16%	3.5x	3.3x	21.9x	17.8x
Inovalon Holdings	\$15.90	89.3%	\$2,464	\$3,344	\$605	\$161	43%	NA	74%	27%	5.5x	5.2x	20.8x	15.8x
Health Catalyst	\$33.94	68.1%	\$1,239	\$1,823	\$141	(\$43)	109%	NA	50%	(30%)	12.9x	11.9x	NMF	NMF
Tabula Rasa Healthcare	\$51.25	64.1%	\$1,132	\$1,326	\$249	\$8	113%	NA	36%	3%	5.3x	4.7x	NMF	36.4x
Vocera Communications	\$20.78	48.8%	\$654	\$548	\$177	(\$7)	9%	NA	62%	(4%)	3.1x	3.0x	NMF	32.3x
Streamline Health Solutions	\$1.29	61.7%	\$39	\$52	\$21	(\$2)	(13%)	NA	66%	(9%)	2.5x	2.4x	NMF	15.7x
MEAN							48%	80%	56%	0%	5.5x	5.1x	21.3x	23.6x
MEDIAN							34%	80%	56%	(0%)	4.4x	4.0x	21.3x	17.8x

Medical Bill Servicing

						Growth	Rates:						
Stock	% of 52-	Market	Enterprise	LT	M	Revenue	Earnings	LTM M	argins:	EV / R	evenue	EV / E	BITDA
Price	Wk. High	Value	Value	Revenue	EBITDA	CY 2019	LT	Gross	EBITDA	LTM	CY 2019	LTM	CY 2019
\$26.53	65.2%	\$2,337	\$2,313	\$626	\$161	26%	49%	36%	26%	3.7x	3.5x	14.4x	12.3x
\$10.81	82.0%	\$1,212	\$1,829	\$1,084	\$50	165%	NA	15%	5%	1.7x	1.5x	36.4x	10.9x
\$29.91	96.5%	\$1,070	\$993	\$110	(\$7)	NA	NA	85%	(6%)	9.0x	NA	NMF	NA
\$31.70	71.4%	\$846	\$799	\$71	\$22	19%	12%	94%	30%	11.2x	10.8x	37.1x	32.0x
\$1.23	83.1%	\$116	\$139	\$223	\$7	(10%)	NA	30%	3%	0.6x	0.6x	18.9x	90.9x
\$1.29	61.7%	\$39	\$52	\$21	(\$2)	(13%)	NA	66%	(9%)	2.5x	2.4x	NMF	15.7x
						37%	31%	54%	8%	4.8x	3.8x	26.7x	32.4x
						19%	31%	51%	4%	3.1x	2.4x	27.6x	15.7x
	\$26.53 \$10.81 \$29.91 \$31.70 \$1.23 \$1.29	Price Wk. High \$26.53 65.2% \$10.81 82.0% \$29.91 96.5% \$31.70 71.4% \$1.23 83.1% \$1.29 61.7%	Price Wk. High Value \$26.53 65.2% \$2,337 \$10.81 82.0% \$1,212 \$29.91 96.5% \$1,070 \$31.70 71.4% \$846 \$1.23 83.1% \$116 \$1.29 61.7% \$39	Price Wk. High Value Value \$26.53 65.2% \$2,337 \$2,313 \$10.81 82.0% \$1,212 \$1,829 \$29.91 96.5% \$1,070 \$993 \$31.70 71.4% \$846 \$799 \$1.23 83.1% \$116 \$139 \$1.29 61.7% \$39 \$52	Price Wk. High Value Value Revenue \$26.53 65.2% \$2,337 \$2,313 \$626 \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$29.91 96.5% \$1,070 \$993 \$110 \$31.70 71.4% \$846 \$799 \$71 \$1.23 83.1% \$116 \$139 \$223 \$1.29 61.7% \$39 \$52 \$21	Price Wk. High Value Value Revenue EBITDA \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 \$29.91 96.5% \$1,070 \$993 \$110 (\$7) \$31.70 71.4% \$846 \$799 \$71 \$22 \$1.23 83.1% \$116 \$139 \$223 \$7 \$1.29 61.7% \$39 \$52 \$21 (\$2)	Stock Price % of 52-Wk. High Market Value Enterprise Value LTM Revenue Revenue \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% \$29.91 96.5% \$1,070 \$993 \$110 (\$7) NA \$31.70 71.4% \$846 \$799 \$71 \$22 19% \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%)	Price Wk. High Value Value Revenue EBITDA CY 2019 LT \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% 49% \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% NA \$29.91 96.5% \$1,070 \$993 \$110 (\$7) NA NA \$31.70 71.4% \$846 \$799 \$71 \$22 19% 12% \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) NA \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%) NA	Stock Price % of 52-Wk. High Market Value Enterprise Value LTM Revenue EBITDA CY 2019 LT Gross \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% 49% 36% \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% NA 15% \$29.91 96.5% \$1,070 \$993 \$110 (\$7) NA NA 85% \$31.70 71.4% \$846 \$799 \$71 \$22 19% 12% 94% \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) NA 30% \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%) NA 66%	Stock Price % of 52-Wk. High Market Value Enterprise Value LTM Revenue EBITDA CY 2019 LT Gross EBITDA \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% 49% 36% 26% \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% NA 15% 5% \$29.91 96.5% \$1,070 \$993 \$110 (\$7') NA NA 85% (6%) \$31.70 71.4% \$846 \$799 \$71 \$22 19% 12% 94% 30% \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) NA 30% 3% \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%) NA 66% (9%)	Stock Price % of 52- Wk. High Market Value Enterprise Value LTM Revenue Earlings LTM Margins: EV / R \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% 49% 36% 26% 3.7x \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% NA 15% 5% 1.7x \$29.91 96.5% \$1,070 \$993 \$110 (\$7) NA NA 85% (6%) 9.0x \$31.70 71.4% \$846 \$799 \$71 \$22 19% 12% 94% 30% 11.2x \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) NA 30% 3% 0.6x \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%) NA 66% (9%) 2.5x	Stock Price % of 52-Wk. High Market Value Enterprise Value LTM Revenue Earrings LTM Margins: EV / Revenue EV / Revenue \$26.53 65.2% \$2,337 \$2,313 \$626 \$161 26% 49% 36% 26% 3.7x 3.5x \$10.81 82.0% \$1,212 \$1,829 \$1,084 \$50 165% NA 15% 5% 1.7x 1.5x \$29.91 96.5% \$1,070 \$993 \$110 (\$7) NA NA 85% (6%) 9.0x NA \$31.70 71.4% \$846 \$799 \$71 \$22 19% 12% 94% 30% 11.2x 10.8x \$1.23 83.1% \$116 \$139 \$223 \$7 (10%) NA 30% 3% 0.6x 0.6x \$1.29 61.7% \$39 \$52 \$21 (\$2) (13%) NA 66% (9%) 2.5x 2.4x	Stock Price % of 52-Wk. High Market Value Enterprise Value LTM Revenue Earnings LTM Margins: EV / Revenue EV / Revenue

Source: Pitchbook

Key M&A Transaction Activity Summary Date Target Acquirer(s) Sector Value (\$mm) Transaction Comments	
Date Target Acquirer(s) Sector (\$mm) Transaction Comments	
 Fitbit develops wearable products that trace and provide motivation for everyday fitnes 4 Analytics 52,100 Fitbit develops wearable products that trace and provide motivation for everyday fitnes Under Google's umbrella, Fitbit seeks to accelerate innovation in its wearable business 	
Automated Medical SYSTENS Automated Medical SYSTENS Core Solutions NA AMS provides software and hardware system for medical practices The acquisition helps DAS broaden its product portfolio and strengthen its position in the U.S. Health IT market	n
11/1/2019 Vivifyhealth ← OPTUM Healthcare IT / Analytics NA ■ Vivify Health operates a cloud-based, device-agnostic remote patient monitoring platform ■ Terms of the transaction were not disclose and both parties declined to comment	
10/24/2019 Health Insurance Solutions Health Navigator provides employee healthcare plans and strategies for businesses and health care providers Amazon will integrate Health Navigator intits newly-launched Amazon Care group	:O
 9/19/2019 qualifacts Warburg Pincus Healthcare IT / Analytics NA Qualifacts develops CareLogic, an EHR platform for behavioral health and human services organizations The acquisition enables Qualifacts to furth refine its products and expand through acquisitions 	er
9/16/2019 VITRECS Healthcare IT / Analytics Sarangement Health Care IT / Analytics Sarangement HMS seeks to strengthen its Population Health Management suite with the integration of VitreosHealth	

Key Fina	ncing Transactio	n Activity Summ	ary		
Date	Target	Sector	Amount (\$mm)	Туре	Key Investor(s)
10/29/2019	sa•na	Health Insurance Solutions	\$3.6	Seed Round	TRUST VENTURES GIGAFUND
10/28/2019	pieriandx	Healthcare IT / Analytics	\$27	Series B	ATW PARTNERS SJF VENTURES
10/28/2019	JSENSELY L	Core Solutions	\$15	Growth Equity	Afrac.
10/24/2019	₽ AUGMEDIX	Healthcare IT / Analytics	\$19	Series B	Redmile Group MSKESSON Empowering Healthcare
10/22/2019	SIGNAL PATH RESEANCH - REWIRES	Healthcare IT / Analytics	\$18	Series B	Private
10/18/2019	W weave	Healthcare IT / Analytics	\$70	Series D	TIGERGLOBAL

IPO	Activity	/ Summary
•	Activity	, Callillai y

Company	IPO Date	Amount Raised (\$mm)	IPO Price	Current Market Price	Total Return	
Health Catalyst ignite outcomes improvement	7/24/2019	\$182	\$26.00	\$33.94	31%	
Phreesia	6/21/2019	\$167	\$18.00	\$29.91	66%	
CHANGE HEALTHCARE	3/22/2019	\$557	\$13.00	\$13.40	3%	
iRhythm*	10/19/2016	\$107	\$17.00	\$68.32	302%	
TABULARASA HEALTHCARE	09/28/2016	\$52	\$12.00	\$51.25	327%	
NANTHEALTH	06/01/2016	\$91	\$14.00	\$0.71	(95%)	
evolent O"	06/04/2015	\$196	\$17.00	\$7.80	(54%)	
inoval on	02/11/2015	\$600	\$27.00	\$15.90	(41%)	
Health Equity	06/30/2014	\$127	\$14.00	\$58.62	319%	
Castlight	03/13/2014	\$178	\$16.00	\$1.54	(90%)	
vocera	03/27/2012	\$94	\$16.00	\$20.78	30%	
R1	05/19/2010	\$120	\$12.00	\$10.81	(10%)	

Market data as of November 1, 2019 Source: Pitchbook



Select Wall Street Research Updates and Commentary

Update from Piper Jaffray, October 2019



Cerner noted they took four DoD sites live, and the next wave is projected to occur in the fall of 2020. They are in the midst of kicking off the Coast Guard project. And the VA officially kicks off in the Spring of 2020. The recent acquisition of Ablevets will provide additional capacity and expertise to partner at the DoD, especially in the areas of cybersecurity, agile development, and general ability to navigate the federal landscape.

Update from Oppenheimer, November 2019



MDRX reported 3Q19 revenues/EPS of \$445M/\$0.17 vs. \$450M/\$0.17 estimates. Bookings grew an impressive 19%, to \$236M, on broad-based strength. The company reaffirmed 4Q and CY19 guidance, narrowing its adjusted EPS range. Allscripts commented that the recent contract extension with top client Northwell was at similar economics and that it expected the managed services contract to also be renewed by year-end. We look forward to 4Q, when the company expects an acceleration in revenue growth, based on current bookings strength.

Update from Edison Investment Research, September 2019



EMIS reported growth in revenues (+7%), adjusted operating profit (+8%) and adjusted EPS (+11%) in H119. Management restructured the business during H1 to reflect the two key customer groups for EMIS products and, with the disposal of the Specialist & Care division, streamlined the product portfolio. Development of EMIS-X continues on track, with the first application based on the platform launched within the Patient Access app. We view the share price as likely to tread water until the outcome of the GP IT Futures procurement process is announced in the next few months.

Update from Citi, November 2019



EVH posted a mostly positive 3Q, with the announcement of the Maryland Physicians Care Medicaid win and a revenue/EBITDA beat vs. Street offset by an EBITDA miss in 4Q guidance and no update on Passport. Notably, the KY Medicaid contract still remains outstanding, but Passport Health has seen improved profitability with a positive operating margin in the quarter. Expected stock price reaction: mild positive, depending on call commentary. We do not expect an outsized reaction with shares down 20% since the Passport deal, and continue to believe shares will remain range-bound until we get clarity on the KY contract renewal.

Update from BMO, October 2019



These very strong, high quality 3Q results bode well for WCG (and for CNC, given their pending merger). Meanwhile, WCG provided bullish directional comments on key 2020 factors (e.g., MA/PDP product positioning vs. competitors). Meanwhile, the strength of 3Q and the outlook comments are timely given WCG is no longer providing guidance (and hasn't since the WCG/CNC deal was announced). We have raised our 2019E EPS to \$15.66 from prior \$14.00 with partial flow through to 2020-2021 (now \$17.25 and \$19.91 vs. prior \$16.30 and \$18.90, respectively). These standalone estimates drive further upside potential under our outlook for the combined entity



Appendix – Coverage Universe Components

The coverage universe for various sectors is as follows:

1 Payments:

PINX:EDNMY, NYS:ADS, NYS:FLT, NYS:WEX, NYS:SHOP, NAS:PYPL, NYS:SQ, PINX:ADYYF, LON:BOKU, NYS:PAGS, NAS:STNE, NYS:EB, NAS:PYPL, NYS:AXP, NYS:MA, NYS:V, NAS:PMTS, NAS:CATM, NYS:DBD, NYS:EVRI, BSP:CIEL3, PAR:WLN, NAS:NEWT, NAS:QIWI, NAS:UEPS, ETR:WDI, NYS:DLX, NYS:EVTC, NYS:GPN, TKS:3769, LON:PAY, NYS:SQ, NYS:TSS, NAS:IIIV, NAS:EVOP, NAS:ACIW, NAS:EPAY, NAS:FISV, NAS:JKHY, NYS:FIS, GREY:INGIF, HKG:327, SHE:2152, NYS:NCR, NYS:PAR, TSE:LSPD, IDX:MCAS, NAS:EEFT, NAS:MGI, NYS:GDOT, ASX:OFX, NYS:WU

2 Bank Technology Solutions:

NAS:INTC, NAS:PYPL, NYS:AXP, NYS:IBM, BOM:532466, BOM:538835, NAS:EPAY, NAS:FISV, NAS:JKHY, PINX:CSVI, SWX:CLXN, NYS:FIS, TKS:6457, NYS:QTWO, SES:5CP, SWX:TEMN, STO:INTRUM, NYS:EFX, LON:EXPN, NYS:FICO, NYS:TRU, NAS:ASPS, NAS:CSGP, NAS:RDFN, NAS:RP, NAS:ZG, NYS:BKI, NYS:CLGX, NYS:FNF, TSE:REAL, NYS:STC, AMS:WKL, PAR:SOP, NAS:MITK, NAS:NTWK, NAS:PEGA, PINX:ASOZY

3 Specialty Finance / Alternative Lending:

NAS:ASFI, NAS:ECPG, NAS:NAVI, NAS:PFMT, NAS:PRAA, NAS:PRGX, NYS:NNI, NAS:CPSS, NAS:CACC, LON:FCH, NAS:MRLN, TSE:CHW, NYS:CIT, ASX:ZTP, NAS:ATLC, NAS:EZPW, NYS:AAN, NAS:FCFS, NAS:SLM, NAS:TBBK, NAS:WRLD, TSE:ECN, NYS:CURO, NAS:GSKY, NYS:AAN, NYS:COF, NYS:DF, NYS:DF, NYS:DF, NYS:DF, NYS:CAN, NYS:COF, NYS:TGH, NYS:CAI, NYS:CAI, NYS:FLY, NYS:TGH, NYS:URI, NAS:CASH, PINX:DHCPQ, NYS:OCN, NYS:PFSI, NAS:TREE, ETR:FRU, STU:MBC, NYS:XRF, NYS:ELVT, NYS:ENVA, NYS:LC, NYS:ONDK, NYS:YRD

4 Securities:

AMS:FLOW, PAR:VIL, IEXG:IBKR, NAS:BGCP, NAS:TW, NAS:VIRT, LON:IGG, NYS:LM, NYS:IVZ, NAS:WETF, NYS:BLK, NYS:BEN, NYS:AB, MEX:FINAMEXO, NAS:INTL, SWX:CFT, MIL:MB, PAR:BNP, NSE:ICICIBANK, NSE:IIFL, PINX:HSNGY, ETR:COM, NYS:AXP, NYS:BAC, LON:BARC, TSE:BMO, TSE:CM, NYS:C, LON:CBG, ASX:CBA, SES:D05, NYS:FII, LON:HSBA, NYS:JPM, NYS:BAC, NYS:HSBC, LON:LLOY, NYS:MTB, ASX:NAB, NYS:PNC, TSE:RY, LON:RBS, TSE:TD, NYS:USB, NYS:WFC, LON:BME, BSP:B3SA3, PAR:ENX, NAS:CME, NAS:NDAQ, PINX:HKXCY, ETR:DB1, ASX:ASX, BATS:CBOE, NYS:ICE, LON:LSE, SES:S68, TSE:X, NAS:VALU, NAS:MORN, NSE:CRISIL, NYS:FDS, NYS:INFO, NYS:MCO, NYS:MSCI, NYS:IT, NAS:FORR, NYS:RELX, NYS:SPGI, TSE:TRI, LON:NUM, NAS:COWN, ETR:DBK, SWX:CSGN, NYS:GHL, NYS:JPM, NYS:JPM, ASE:LTS, NYS:LAZ, ASX:MQG, NYS:MS, TKS:8604, NYS:PJC, NYS:RJF, NYS:SF, NYS:GS, SWX:UBSG, NYS:AB, NYS:AMP, NYS:APAM, NYS:BLK, NYS:BK, NYS:CNS, NYS:BEN, LON:HL., NYS:IVZ, NYS:JHG, NAS:NTRS, NAS:SEIC, NAS:UMBF, NYS:MTB, NAS:TROW, NAS:VRTS, NYS:WDR, NAS:WETF, NYS:SCHW, LON:CMCX, NAS:ETFC, NYS:GCAP, NAS:MKTX, TKS:8628, NAS:VIRT, IEXG:IBKR, NAS:TIGR, NAS:FHL, TKS:8698, LON:PLUS, SWX:SQN, NAS:AMTD, NAS:YIN, AMS:KA, NAS:LPLA, NYS:AMK, NAS:SEIC, ASX:BVS, SWX:TEMN

5 Insurance:

NAS:BNFT, NAS:HQY, NAS:PAYX, NAS:WDAY, NYS:NSP, NYS:TNET, NAS:VRSK, NYS:RAMP, LON:REL, NYS:CLGX, NYS:FICO, NAS:WLTW, NYS:AON, NYS:AJG, NYS:BRO, NYS:MMC, NAS:GSHD, PINX:AZSEY, PINX:AXAHY, NYS:ALL, NYS:AFG, NYS:AIG, SWX:ZURN, NAS:EVER, NAS:EHTH, NAS:ONST, LON:GOCO, ASX:ISU, LON:MONY, NAS:CINF, NAS:SIGI, NAS:STFC, NYS:CB, NYS:EIG, NYS:MCY, NYS:PGR, LON:RSA, NYS:THG, NYS:HIG, NYS:TRV, HKG:6060, NAS:AMSF, NAS:GBLI, NYS:ARGO, NYS:AIZ, NYS:MKL, NYS:PRA, NYS:RLI, NYS:WRB, NAS:SPNS, NAS:MJCO, NAS:EBIX, NYS:CRD.B, NYS:GWRE, NYS:FNF, NYS:FAF, NYS:ORI, NYS:STC, PINX:AEGOF, NAS:ANAT, NAS:PFG, NYS:AFL, LON:AV., NYS:CI, TSE:GWO, LON:HSD, LON:LGEN, NYS:LNC, TSE:MFC, NYS:MET, NYS:PRI, NYS:PRU, LON:SLA, TSE:SLF, SWX:SLHN, NYS:GL

6 BPO:

PINX:TLPFY, NAS:SYKE, NAS:TTEC, BSP:QUAL3, NAS:CPSI, NAS:HMSY, NAS:HQY, NAS:MDRX, NAS:NXGN, NAS:RCM, NYS:CSLT, NAS:BNFT, NAS:ADP, NAS:CSOD, NAS:PAYX, NYS:NSP, NYS:TNET, MIL:BET, BOM:507685, NYS:ATO, PINX:CGEMY, NAS:OSPN, NAS:CTSH, NAS:DOX, NAS:EXLS, TSE:OTEX, NAS:VRTU, NSE:HCLTECH, NSE:HEXAWARE, NSE:INFY, NSE:MINDTREE, NSE:TCS, NSE:TECHM, NYS:ACN, LON:APTD, NYS:CACI, NYS:DXC, NYS:UIS, NYS:WNS, LON:IBPO, BOM:526299, BOM:532809, NAS:PRGX, LON:CPI, TSE:GIB.A, NYS:G

7 Financial Management Solutions:

NAS:BL, NAS:COUP, NAS:INTU, ASX:RKN, NAS:DOCU, LON:SGE, NYS:AVLR, ASX:XRO, NAS:MSTR, NAS:SPLK, NYS:TDC, NAS:AMSWA, NAS:APPN, NAS:EPAY, NYS:PLAN, PINX:BPRMF, LON:APTD, NAS:PEGA, NAS:QADA, NSE:RAMCOSYS, ASX:TNE, BSP:TOTS3, NYS:TYL, NAS:ADP, NAS:CSOD, NYS:CDAY, NAS:PAYX, NAS:PCTY, NAS:WDAY, NYS:HRB, NYS:NSP, NYS:PAYC

8 Enterprise Software / Data & Analytics:

ETR:SAP, NAS:VERI, NAS:MSTR, TSE:OTEX, NAS:SPLK, PINX:STWRY, NYS:AYX, NAS:WDAY, NYS:MDLA, NAS:CDLX, NYS:CLDR, LON:EXPN, NYS:FICO, NYS:NEWR, NYS:ORCL, NYS:CRM, NYS:VMW, HEL:NOKIA, GREY:SSNLF, NAS:AMBA, NAS:AMZN, NAS:CMCSA, NAS:GOOGL, NAS:GRMN, NAS:LOGN, NAS:LOGN, NAS:MSFT, NAS:QOOM, NAS:SLAB, NAS:TMUS, NYS:T, NYS:FIT, NYS:GLOB, NYS:S, NYS:VZ, ETR:SAP, NYS:ZUO, NYS:ORCL, NYS:IBM, NYS:CRM, NAS:ADBE, NAS:MSFT, NYS:VMW, NAS:SYMC, NAS:PEGA, NAS:FORR, NAS:VRSK, TSE:AIM, NYS:CLGX, NYS:EFX, NYS:IT, NYS:IBM, NYS:RAMP, LON:REL, NYS:TDC, NYS:NLSN, NYS:TRU

9 Healthcare Tech:

LON:EMIS, NAS:CERN, NAS:CPSI, NAS:HSTM, NAS:MDRX, NAS:NXGN, ETR:COP, NAS:NH, NYS:EVH, NAS:HIIQ, NAS:MGLN, NAS:NUAN, NYS:ANTM, NYS:CNC, NYS:HUM, NYS:MMS, NYS:MOH, NYS:GTS, NYS:UNH, NYS:WCG, NAS:STRM, NAS:TRHC, NAS:HCAT, NAS:INOV, NAS:OMCL, NYS:VCRA, LON:CRW, NAS:STRM, NYS:PHR, NAS:HMSY, NAS:CHNG, NAS:RCM, NAS:SREV





DISCLAIMER

The principals of Evolve Capital Partners are registered representatives of BA Securities, LLC Member FINRA SIPC, located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 400 W. Conshohocken, PA 19428. Evolve Capital Partners and BA securities, LLC are unaffiliated entities. All investment banking services are offered through BA Securities, LLC, Member FINRA SIPC. This presentation is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer or invitation and shall not form the basis of any contract with BA Securities, LLC.

The information in this presentation is based upon Evolve Capital Partners estimates and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. In preparing this presentation, we have relied upon and assumed, without independent verification, the accuracy and completeness of information available from public sources. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. Neither BA Securities, LLC nor Evolve Capital Partners makes any representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. BA Securities, LLC and Evolve Capital Partners do not render legal or tax advice, and the information contained in this communication should not be regarded as such.

The information in this presentation does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.

If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this presentation is prohibited.

KEY SENIOR PROFESSIONAL

Alexander Koles

Founder, CEO, Managing Director akoles@evolve-capital.com

Mr. Koles has over 15 years of financial advisory experience including advising middle-market and multinational firms on merger and acquisition strategies and execution, restructurings and capital raises. Prior to founding Evolve Capital Partners, he worked at a number of leading investment banks in leadership roles focused on restructuring transactions. He started his career at Merrill Lynch as an investment banker in the corporate finance group.

CONTACT

Evolve Capital Partners

1350 Avenue of the Americas 2nd Floor New York, NY 10019 T: (646) 688-2792 evolve-capital.com